Noncoding RNAs are an emerging class of nonpeptide regulators of metabolism. Metabolic diseases and the altered metabolic environment induce marked changes in levels of microRNAs and long noncoding RNAs. Furthermore, recent studies indicate that a growing number of microRNAs and long noncoding RNAs serve as critical mediators of adaptive and maladaptive responses through their effects on gene expression. The metabolic environment also has a profound impact on the functions of classes of noncoding RNAs that have been thought primarily to subserve housekeeping functions in cells—ribosomal RNAs, transfer RNAs, and small nucleolar RNAs. Evidence is accumulating that these RNAs are also components of an integrated cellular response to the metabolic milieu. This Perspective discusses the different classes of noncoding RNAs and their contributions to the pathogenesis of metabolic stress.

Much of the morbidity and mortality in diabetes relates to complications that result from the underlying metabolic alterations in this disease. In type 2 diabetes, hyperlipidemia, as well as hyperglycemia, have been implicated as triggers for complications that impact the heart, liver, kidney, and the endothelium of blood vessels of many tissues including the eye (1–4). Furthermore, these metabolic stressors have been implicated in the decline in β-cell function that contributes to progressive insulin insufficiency and eventual requirement for insulin therapy in type 2 diabetes (5).

High levels of circulating glucose, fatty acids, and triglycerides result in delivery of quantities of substrates that exceed the ability of tissues to safely metabolize or store these molecules. Glucotoxicity, lipotoxicity, and glucolipotoxicity engage endoplasmic reticulum stress and oxidative stress pathways that cause organ dysfunction and, in some cases, cell death (6). Protein-mediated signaling clearly plays important roles in these metabolic stress responses, and metabolic stress–induced changes in gene expression have been described in many cell types and physiological contexts. With the advent of high-throughput RNA sequencing technologies over the past 15 years, there is a growing appreciation of the functional role of noncoding RNAs in physiological and pathological processes. This review will focus on noncoding RNAs that play key roles in directing cell and tissue responses to lipotoxicity and glucotoxicity.

microRNA

Since their initial discovery in the mid-1990s, microRNAs (miRNAs) have come to be recognized as a ubiquitous class of noncoding RNA modulators of mammalian physiological responses that act through posttranscriptional regulation of gene expression. Primary miRNA molecules are generated by RNA polymerase II from independent transcriptional units or from mirtrons embedded within the introns of protein coding genes, and they are processed by the enzymes Drosha and Dicer to generate miRNAs of 19–23 nucleotides in length (7). These mature miRNAs are loaded onto Argonaute proteins to form the functional RNA-induced silencing complex that targets complementary sites within mRNAs, leading to degradation of the mRNA in most cases or inhibition of translation in rare instances (8).

Observations that levels of some miRNAs are regulated by lipotoxic and glucotoxic conditions have implicated these noncoding RNAs in the pathogenesis of diabetes complications. Microarray analyses have revealed that in the MIN6 pancreatic β-cell line, more than half of the 108 detectable miRNAs are glucose regulated (9), whereas relatively fewer miRNAs are regulated by prolonged exposure to lipids (10). However, only a subset of these glucose- and lipid-regulated miRNAs have been demonstrated to function in the pathophysiological response to metabolic stress (Fig. 1).
Abundance of miRNAs can be regulated at the level of transcription, processing, and/or degradation. While the molecular details of transcriptional and processing steps of many miRNAs are well understood, relatively less is known about how these small RNAs are degraded. For most metabolic stress–regulated miRNAs, future studies will be required to determine the mechanisms that lead to altered abundance of the miRNA.

**Table 1—miRNAs that function in metabolic stress**

| miRNA   | Context            | Target          | Function                          | Change in metabolic stress       |
|---------|--------------------|-----------------|-----------------------------------|----------------------------------|
| **Maladaptive** |
| miR-34a | MIN6 β-cells       | Bcl2, VAMP2     | Promotes lipotoxic cell death     | Induced by palm                  |
| miR-146 | MIN6 β-cells       | Bcl2, sirtuin1  | Promotes lipotoxic cell death     | Induced by palm                  |
| miR-195 | Cardiomyocytes     | Bcl2, PUMA      | Inhibits apoptosis                | Decreased by palm                |
| miR-296 | Hepatocytes        | CHOP            | Inhibits apoptosis                | Decreased by palm                |
| miR-615-3p | Ilets, MIN6 β-cells | Hnf1α, Neurod1 | Inhibits proliferation, insulin secretion | Induced by palm and HFD          |
| miR-375 | Ilets, β-cells     | Pdk1            | Dampens phosphatidylinositol 3-kinase signaling | Induced by high glucose          |
| miR-30a-5p | Ilets, β-cells   | Beta2/NeuroD    | Decreases transcription of Ins, Sur1 | Induced by high glucose          |
| miR-214 | Monocytes          | Pten            | Prolongs inflammation             | Induced by AGEs                  |
| miR-21  | Renal mesangial cells | Pten         | Increases AKT and TORC1 activation | Induced by high glucose          |
| miR-9a-3p | Vascular SMCs     | Sur2b           | Compromises K<sub>ATP</sub> channel function | Induced by methylglyoxal         |
| miR-29c | Renal ECs, podocytes | Spry1          | Increases extracellular matrix, apoptosis | Induced by hyperglycemia, DM      |
| miR-503 | ECs                | Cdc25A          | Inhibits proliferation, migration | Induced by glucose, DM           |
| **Adaptive** |
| miR-195 | Retinal ECs        | Sirt1           | Limits senescence                 | Induced by high glucose          |
| miR-93  | Podocytes          | VEGF            | Limits microvascular complications | Decreased by hyperglycemia       |
| miR-124a | INS-1 β-cells     | FOXA2           | Decreases islet amyloid polypeptide | Decreased by hyperglycemia       |
| miR-200a-3p | Renal mesangial cells | TGFβ          | Decreases fibrosis                | Decreased by high glucose        |
| miR-200b | Retinal ECs        | VEGF            | Decreases vascular permeability   | Decreased in DM                  |

DM, diabetes; ECs, endothelial cells; HFD, high-fat diet; palm, palmitate; SMCs, smooth muscle cells.
Several miRNAs contribute to cell death after prolonged exposure of cells in culture to media containing pathophysiologically high concentrations of the saturated fatty acid palmitate. In MIN6 cells, palmitate induces expression of miR-34a and miR-146 (10). Overexpression of either miRNA enhances, whereas knockdown inhibits, palmitate-induced apoptosis of MIN6 cells. Targets of miR-34a in these cells include Bcl2, an important antiapoptotic regulator, as well as VAMP2, which plays a critical role in exocytosis of insulin granules, providing a mechanistic understanding of the contribution of miR-34a to cell dysfunction and cell death. In cardiomyocytes, Bcl2 and sirtuin 1 are targeted by palmitate-induced miR-195, resulting in changes in gene expression that promote apoptosis (11). On the other hand, lipotoxic conditions also decrease expression of miRNAs that target proapoptotic proteins and can thus disrupt constitutive prosurvival functions. Incubation of hepatocytes with palmitate decreases generation of miR-296, which leads to increased expression of its proapoptotic target p53 upregulated modulator of apoptosis (PUMA), whereas forced overexpression of this miR-296 decreases PUMA expression and protects against lipotoxicity (12). Similarly, decreases in miR-615-3p under lipotoxic conditions have been linked to increases in expression of CHOP, a proapoptotic transcription factor that is induced during lipopapoptosis (13,14). Beyond the inverse relationship between miRNA abundance and putative target expression for each of these palmitate-regulated miRNAs, experiments using reporter constructs have identified functional binding sites in the 3′-untranslated region of the putative targets. Nonetheless, no studies to date have captured these miRNAs with their targets within the RNA-induced silencing complex.

Lipid-induced miRNAs also drive dysfunctions of some cell types under lipotoxic conditions. miR-24 is highly upregulated in islets isolated from db/db mice and from wild-type mice fed a high-fat diet (15). Furthermore, in MIN6 cells, palmitate induces miR-24, and overexpression of miR-24 inhibits MIN6 cell proliferation, an effect that is mediated through miR-24 downregulation of Hnf1α and Neurod1. Overexpression of miR-24 also decreases glucose- and potassium-stimulated insulin secretion. By contrast, knockdown of miR-24 in islets from HFD mice restores normal glucose-stimulated insulin secretion. Thus, a single miRNA induced during lipid stress can have broad impact on normal tissue function, presumably through its effects on multiple RNA targets.

High glucose and its resulting metabolites, such as advanced glycation end products (AGEs) and methylglyoxal, also induce expression of miRNAs that contribute to cellular dysfunction. In primary islets and β-cell lines, high glucose increases expression of miR-375 and miR-30a-5p, which contribute to impairment of glucose-stimulated insulin secretion by targeting 3′ phosphoinositide-dependent protein kinase-1 (Pdpk1) and Beta2/Neurod, respectively (16,17). Decreases in PDPK1 expression dampen phosphatidylinositol 3-kinase signaling, whereas BETA2/NEUROD is a transcription factor that regulates transcription of the insulin gene and the SUR1 subunit of the K<sub>ATP</sub> channel. Interestingly, high-level expression of miR-375 has been found in postmortem studies of pancreases from humans with type 2 diabetes (18). Several other miRNAs upregulated by glucose target the phosphatase and tensin homolog (Pten) miRNA—in monocytes treated with AGE, miR-214 downregulates PTEN expression and prolongs inflammation (19), and in glucose-treated renal mesangial cells, miR-21–mediated decreases in PTEN expression lead to increased AKT and TORC1 activation (20). Treatment of vascular smooth muscle cells with the reactive carbonyl species methylglyoxal, a by-product of persistent hyperglycemia, induces miR-9a-3p, which targets the mRNA encoding the sulfonylurea receptor 2B (SUR2B) subunit of the vascular K<sub>ATP</sub> channel, thereby compromising K<sub>ATP</sub> channel function (21). Overall, these glucose-induced miRNAs are expressed in a context that is consistent with a potential role in progressive cellular dysfunction.

On the other hand, many miRNAs serve an adaptive role in the face of metabolic stress. Some, like miR-195, are induced by treatment of cultured endothelial cells with high glucose and are also found to be upregulated in the diabetic retina (22). Experiments using an miR-195 antagonist demonstrate that this miRNA functions to limit hyperglycemia-induced senescence of cultured endothelial cells though downregulation of Sirt1. By interfering with the expression of this key mediator of glucose-induced damage to microvessels, miR-195 may protect against retinal complications of hyperglycemia. There are also miRNAs that serve a protective role under homeostatic conditions but whose expression is diminished by hyperglycemia. miR-93 targets vascular endothelial growth factor (VEGF), high levels of which have been implicated in diabetes microvascular complications (23). Hyperglycemia downregulates miR-93 in both the diabetic kidney and in cultured podocytes, and in podocytes transcriptional downregulation of miRNA-93 is associated with excessive secretion of VEGF. miR-124a is another example of an miRNA that physiologically serves to maintain homeostasis in cultured INS-1 β-cells by targeting the transcription factor FOXA2, the net effect of which decreases expression of islet amyloid polypeptide (24). Levels of miR-124a are downregulated by glucose-induced thioredoxin-interacting protein (TXNIP). As deposits of islet amyloid polypeptide are associated with islet degeneration in type 2 diabetes, this observation implicates glucose-induced downregulation of miR-124a in progressive loss of functional β-cells.

Although levels of many miRNAs are altered in the serum and in tissues affected by complications in human subjects with type 1 or type 2 diabetes (25,26), causal relationships among altered miRNA expression, metabolic substrate excess, and pathogenesis of complications are difficult to establish in humans. In contrast, studies in rodent models, in which miRNAs are targeted biochemically or genetically, have provided key insights into their contributions to
the response to metabolic stress. Nonetheless, while there are many examples in which manipulation of miRNA expression leads to anticipated changes in target mRNA expression in animal models (27,28), only in a few instances have such changes been functionally linked to the pathogenesis of complications.

Two glucose-regulated miRNAs play a role in the development of renal abnormalities in diabetes mouse models. High glucose induces expression of miR-29c, which directly targets sprouty homolog 1 (Spry1), a negative regulator of Rho kinase and Wnt signaling that is known to promote diabetic nephropathy (29). In db/db mice, antisense oligo knockdown of miR-29c decreases albuminuria and mesangial matrix accumulation, hallmarks of diabetic nephropathy. By contrast, high glucose downregulates miR-200a-3p, a negative regulator of profibrotic genes such as TGF-β (30). Treatment of mice with a lentiviral short hairpin RNA targeting miR-200a-3p exacerbates urinary albumin excretion and renal fibrogenesis in streptozotocin-treated mice.

Furthermore, a number of miRNAs, which are regulated by glucose in cell culture and dysregulated in tissues of diabetic mice, have been shown to contribute to vascular abnormalities in diabetes models relevant to retinopathy. In retinal capillary endothelial cells of streptozotocin-treated rats, decreased miR-200b is associated with upregulation of both mRNA and protein for its target VEGF, similar to effects observed in glucose-treated endothelial cells (31). Injection of miR-200b mimic or antagonist into the vitreous cavity causes anticipated changes in the abundance of miR-200b and corresponding changes in its VEGF target. Treatment with miR-200b mimic mitigates against effects observed in glucose-treated endothelial cells (31). The mechanism through which miR-200b functions in lipotoxic stress is unknown, during DNA damage–induced cell cycle arrest, miR-200b binds to TAR DNA-binding protein (TDP-43), causing destabilization of cyclin-dependent kinase 6 (Cdk6) mRNA (35). Knockdown of Gadd7 preserves the levels of Cdk6 mRNA and protein and prevents G1/S-phase arrest after genotoxic stress. Whether Gadd7 similarly regulates cell cycle changes during metabolic stress responses remains to be explored.

The most compelling evidence for a role of lncRNAs in the response to the altered metabolic environment and the pathophysiology of diabetes complications comes from studies of glucose-regulated lncRNAs in diabetic retinopathy. MALAT1 is upregulated in retinal endothelial cells cultured in high glucose, in the retinas of streptozotocin-treated mice and rats and mice that demonstrate impaired electoretinograms, and in the fibrovascular membranes and aqueous humor from the eyes of human subjects with diabetic retinopathy (36,37). Knockdown of MALAT1 in rodents using intraocular injection of short hairpin RNA improves retinal function as documented by electoretinograms, decreases apoptotic retinal cell death, and improves survival of retinal pericytes and decreases retinal vascular leakage. In cultured endothelial cells, knockdown of MALAT1 significantly decreases endothelial cell migration and tube formation, both of which may contribute to progression of retinopathy. The precise mechanism of these MALAT1 effects are not known, but experiments using chemical inhibitors of signaling molecules suggest that p38 MAPK signaling pathways are likely to be important downstream effectors (37). Another lncRNA that is induced by culture of cells in high glucose, myocardial infarction–associated transcript 1 (MIAT1), is also upregulated in the retinas of diabetic rodent models (38). Similar to MALAT1, knockdown of MIAT1 in vivo improves visual function and decreases loss of pericytes by apoptosis. MIAT1 acts in a regulatory loop with miR-150-5p, an miRNA that...
targets and represses VEGF expression in the setting of vascular stress. The observation that MIAT1 contains miR-150-5p–binding sites suggests that this lncRNA functions as a sponge to sequester miR-150-5p and thereby effectively repress VEGF mRNA expression.

RNA sequencing studies have revealed other lncRNAs that are dysregulated in the setting of metabolic stress. More than 1,000 lncRNAs are expressed in human islets, approximately half of which are specific for pancreatic tissue (39). Expression of two of these, HILNC-78 (TCL1 upstream neural differentiation–associated RNA [TUNAR]) and Hi-LNC80 (oligodendrocyte maturation–associated long intergenic noncoding RNA [OLMALIN]), are induced in both human and mouse islets in culture media containing high glucose. However the functional contribution of these lncRNAs to β-cell dysfunction or the pathophysiology of diabetes is not known. In another cell type, RNA sequencing analysis of macrophages isolated from diabetic db/db mice revealed 171 differentially expressed lncRNAs (40). One of the most highly expressed, E330013P06 (E33), is upregulated when monocytes are cultured in high glucose, and its overexpression sensitizes macrophages to lipopolysaccharide-induced activation, cytokine production, and foam cell transformation. Interestingly, this lncRNA is also upregulated in monocytes from patients with diabetes. Given the importance of inflammation in diabetes complications, future studies to probe its contribution to tissue dysfunction and damage during metabolic stress will be of interest. Finally, another avenue of discovery for lncRNAs relevant to metabolic stress will be further characterization of the broad classes of lncRNAs induced by ROS (41), since glucose and lipid metabolic stress induce ROS in cultured cells and since tissue damage in diabetes is accompanied by evidence of oxidative stress. As with miRNAs, lncRNAs impact the biology of metabolic stress responses at the level of downstream gene expression (Fig. 1). The many pre- and posttranscriptional mechanisms through which lncRNAs can function suggest that the roles of these noncoding RNAs in metabolic stress will be similarly diverse.

**RIBOSOMAL RNA**

Ribosomal RNAs (rRNAs) are among the most transcribed and the most abundant RNAs in mammalian cells. Together, the 28S, 18S, 5S, and 5.8S mature rRNAs provide the structural framework for ribosomal proteins and facilitate the extension of nascent peptide chains through the peptidyl transferase ribozyme. Generation of ribosomes is highly regulated spatially, with ribosomal DNA genes and transcriptional and processing machinery clustered in nucleoli. Chemical agents known to cause oxidative stress induce nucleolar stress with impairment of rRNA gene transcription, leak of nucleolar proteins to the cytoplasm, and cell cycle arrest (42). When prolonged, such as occurs with knockdown of rRNA transcription factors, nucleolar stress leads to PS3-mediated apoptosis (43). As yet, no studies have established whether the underlying metabolic perturbations in diabetes cause cell death through nucleolar stress, though it is plausible that high glucose or lipid could trigger this pathway.

Like other cellular macromolecules, rRNAs are likely to be impacted by the oxidative stress that accompanies glucotoxicity and lipotoxicity. In yeast, oxidative stress leads to endonucleolytic cleavage of the 25S and 5.8S rRNAs (44). The integrity of rRNA in the setting of hyperglycemia and hyperlipidemia has not been studied. However, in patients with diabetes, the products of oxidative modification of rRNA are observed in the urine, and abundance of these species is linked to all-cause and diabetes-related mortality (45). rRNAs that are damaged by cleavage or oxidative modifications are likely to be sequestered and degraded through a specialized form of autophagy, termed ribophagy (46). Effects of the altered metabolic environment on rRNA integrity and abundance may contribute to the observed decreased RNA content and rates of protein synthesis in models of poorly controlled diabetes (47).

**TRANSFER RNA**

Transfer RNAs (tRNAs) are critical noncoding RNA components of the translational machinery that serve as adapters to deliver amino acids to nascent peptide chains in accordance with mRNA-specified codons. tRNAs undergo extensive processing and posttranscriptional modification, which are required for proper tRNA folding, stability, and function (48). Oxidative stress, a major component of lipotoxicity and glucotoxicity, and DNA damage dynamically reprogram tRNA methylation in yeast through the actions of specific tRNA methyltransferases (49,50). The resulting changes in tRNA modifications alter codon–anticodon interactions in ways that impact translational efficiency of select classes of genes to protect against oxidative stress. Metabolic stress–mediated modifications of tRNA modifications could contribute to the altered programs of gene expression associated with complications in tissues of diabetic animals.

Global and programmatic changes in gene expression in metabolic stress could also result from endonucleolytic cleavage of mature tRNAs, which is known to be potently induced by oxidative stress (51,52). tRNA cleavage, commonly within the accessible anticodon loop, is mediated by the RNase angiogenin. The resulting tRNA halves can interact with translational machinery to inhibit translation initiation or cause translational arrest and stress granule assembly, even in the absence of changes in total tRNA levels (53). Translational reprogramming is critical for cellular adaptations to stress stimuli, such as oxidative stress, and studies exploring tRNA cleavage in response to glucotoxic and lipotoxic stress could uncover mechanisms of metabolic stress–induced translational alterations (54).

**SMALL NUCLEOLAR RNA**

Small nucleolar RNAs (snoRNAs), noncoding RNAs that range from 60 to 300 nucleotides in length, are named for their cellular localization within the nuclear subcompartment,
Where they participate in processing and modification of nascent rRNAs and small nuclear RNAs. Most mammalian snoRNAs are encoded within the introns of RNA polymerase II–transcribed genes and processed out of intron lariats during splicing, although a small number are independently transcribed from their own promoters by RNA polymerase III. Mature snoRNAs complex with proteins to form a machinery that precisely directs posttranscriptional modification of rRNAs and spliceosomal RNAs through Watson–Crick base pairing of their antisense element with the appropriate target RNA (55). Short sequence motifs define box C/D and box H/ACA classes of snoRNAs that associate with different proteins to guide 2′-O-methylation or pseudouridylation, respectively, on their target RNAs. In addition to these canonical functions, some snoRNAs have been implicated in directing alternative mRNA splicing, and others have been found to be processed to smaller, miRNA-like fragments that regulate gene expression posttranscriptionally (56,57).

Another novel function for snoRNAs was identified in a genetic screen designed to elucidate regulators of cell death in response to metabolic stress in mammalian fibroblasts (14). In this study, disruption of the Rpl13a locus by a promoter trap retrovirus enhanced cell survival in media containing lipotoxic concentrations of palmitic acid and high glucose. Genetic complementation of the mutant and knockdown experiments in wild-type cells revealed that loss of a family of box C/D snoRNAs encoded within four introns of the gene, and not the cDNA, is a critical determinant of the response to metabolic and oxidative stress. Furthermore, knockdown of these snoRNAs in the livers of mice protects against propagation of ROS and oxidative tissue damage. While haploinsufficiency of the Rpl13a snoRNAs is sufficient to protect against metabolic stress in the mutant cell line, predicted rRNA targets for these box C/D snoRNAs (U32a, U33, U34, and U35a) remain 2′-O-methylated, indicating that the role for these snoRNAs in metabolic stress likely involves other, yet to be identified targets. The observation that these snoRNAs accumulate in the cytoplasm during metabolic and oxidative stress further suggests the possibility of novel RNA targets in the cytoplasm (58). The mechanism of action of these noncoding RNAs and elucidation of potential roles in the pathology of diabetes complications are active areas of investigation.

While it is possible that snoRNAs, including those from the Rpl13a locus, target mRNAs or other cytosolic RNAs to impact gene expression posttranscriptionally, recent studies also provide support for a novel signaling role involving the RNA-dependent protein kinase (PKR). PKR is a pattern recognition receptor that activates innate host antiviral mechanisms in response to both double-stranded RNA and metabolic stress (59,60). Genetic and diet-induced models of obesity exhibit increased activation of PKR in white adipose tissue and liver, and acute lipid infusion in vivo and lipotoxic conditions in vitro are sufficient to activate PKR (60). A recent study found that snoRNAs are the major class of PKR-bound RNAs under lipotoxic conditions (61). Furthermore, overexpression of SNORD113, SNORA23, or SNORA71 is sufficient to induce PKR activation and phosphorylation of eIF2α, leading to stress-induced alterations in translation. PKR also directly phosphorylates and inhibits insulin receptor substrate 1, and PKR knockout mice are protected from high-fat diet–induced hyperglycemia and hyperinsulinemia (60).

Whether phosphorylation of specific downstream targets by PKR is regulated by specific snoRNAs or combinations of snoRNAs remains to be determined.

**CONCLUSIONS AND FUTURE DIRECTIONS**

We are only beginning to understand how different classes of noncoding RNAs impact the response of cells and tissues to the altered metabolic environment. Abundance of miRNAs and lncRNAs is regulated by abnormal substrate levels. While it is largely assumed that alterations in the levels of these noncoding RNAs reflect differences in transcription, future studies will be required to address whether changes in transcription or processing contribute to the observed altered abundance or whether metabolic stress impacts the RNA half-life. In the case of rRNAs and tRNAs, regulated degradation and covalent modifications do contribute to metabolic stress responses (Fig. 2). Recent studies of snoRNAs suggest that this class of noncoding RNA is differentially localized in response to changes in the metabolic milieu. Whether or not altered localization correlates with noncanonical targets remains to be determined.

While different classes of noncoding RNAs engage downstream targets and pathways in diverse ways, each can profoundly impact gene expression and the response to environmental challenge. A greater understanding of noncoding RNA pathways has the potential to provide new insights not only into metabolic regulation but also into phenotypic variation in metabolic diseases that is not
explained by alterations in exonic sequences. Furthermore, over the past several years, approaches using antisense oligonucleotides directed against miRNAs (i.e., anti-miRs) have been shown to hold promise in reducing the levels of the target miRNAs and modifying disease phenotypes in murine disease models, including hyperlipidemia (62,63). It is intriguing to consider that such approaches may be useful in preventing complications in patients with diabetes. Looking to the future, it is also possible to envision new therapeutic approaches that target IncRNAs and snoRNAs—classes of noncoding RNAs that are also amenable to antisense strategies.

Acknowledgments. The authors thank Daniel Ory of Washington University for critical review of the manuscript.

Funding. Work in the laboratory of J.E.S. is supported by the National Institutes of Health (R01-DK-064989 and R01-DK-103837) and Fondation Leducq.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Prior Presentation. Parts of this study were presented in abstract form at the 76th Scientific Sessions of the American Diabetes Association, New Orleans, LA, 10–14 June 2016.

References
1. Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab 2012;15:805–812
2. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147–152
3. Yao F, Li Z, Ehara T, et al. Fatty acid-binding protein 4 mediates apoptosis via endoplasmic reticulum stress in mesangial cells of diabetic nephropathy. Mol Cell Endocrinol 2015;411:232–242
4. Kumar B, Kowluru A, Kowluru RA. Lipotoxicity augments glucotoxicity-induced mitochondrial damage in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2015;56:2985–2992
5. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95:2498–2502
6. Brookheart RT, Michel CI, Listenberger LL, Ory DS, Schaffer JE. The non-coding RNA gadd7 is a regulator of lipid-induced oxidative and endoplasmic reticulum stress. J Biol Chem 2009;284:7446–7454
7. Filipowicz W, Bhattacharya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008;9:102–114
8. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target miRNA levels. Nature 2010;466:835–840
9. Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic (beta) cells reveals a role for miR-30d in insulin transcription. RNA 2009;15:287–293
10. Loewis F, Roggli E, Laybutt DR, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes 2008;57:2728–2736
11. Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011;92:75–84
12. Cazanave SC, Mott JL, Elmi NA, et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J Lipid Res 2011;52:1517–1525
13. Miyamoto Y, Mauer AS, Kumar S, Mott JL, Malhi H. Mmu-miR-615-3p regulates lipoapoptosis by inhibiting C/EBP homologous protein. PLoS One 2014;9:e109637
14. Michel CI, Holley CL, Scruggs BS, et al. Small nucleolar RNAs U32a, U33, and U35a are critical mediators of metabolic stress. Cell Metab 2011;14:33–44
15. Zhu Y, You W, Wang H, et al. MicroRNA-24/MODY gene regulatory pathway mediates pancreatic beta-cell dysfunction. Diabetes 2013;62:3194–3206
16. El Ouasaami A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008;57:2706–2717
17. Kim JW, You YH, Jung S, et al. miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models. Diabetologia 2013;56:847–855
18. Zhao H, Guan J, Lee HM, et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficient and islet amyloid deposition. Pancreas 2010;39:843–846
19. Li LM, Hou DX, Guo YL, et al. Role of microRNA-214-targeting phosphatase and tensin homolog in advanced glycation end product-induced apoptosis delay in monocytes. J Immunol 2011;186:2552–2560
20. Dey N, Das F, Mariappan MM, et al. MicroRNA-21 orchestrates high glucose-induced signals to TGF-β complex 1, resulting in renal cell pathology in diabetes. J Biol Chem 2011;286:25586–25603
21. Li SS, Wu Y, Jin X, Jiang C. The SUR2B subunit of rat vascular KATP channel is targeted by miR-9a-3p induced by prolonged exposure to methylglyoxal. Am J Physiol Cell Physiol 2015;309:C139–C145
22. Mortuza R, Feng B, Chakrabarti S. miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 2014;57:1037–1046
23. Long J, Wang Y, Wang W, Chang BH, Danesh FR. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 2010;285:23457–23465
24. Jing G, Westwell-Roper C, Chen J, Xu G, Verchere CB, Shalev A. Thioredoxin-interacting protein promotes islet amyloid polypeptide expression through miR-124a and FoxA2. J Biol Chem 2014;289:11807–11815
25. Greco S, Fasanaro P, Castelvecchio S, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012;61:1633–1641
26. Herrera BM, Lockstone HE, Taylor JM, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010;53:1099–1109
27. Xiang Y, Cheng J, Wang D, et al. Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of von Willebrand factor. Blood 2015;125:3377–3387
28. Feng B, Chen S, McArthur K, et al. miR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011;60:2975–2984
29. Long J, Wang Y, Wang W, Chang BH, Danesh FR. MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 2011;286:11837–11848
30. Wei J, Zhang Y, Luo Y, et al. Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-1R NF-κB, Tgfβ/1,2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice. Free Radic Biol Med 2014;67:91–102
31. McArthur K, Feng B, Wu Y, Chen S, Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011;60:1314–1323
32. Caporali A, Meloni M, Vollenkle C, et al. Deregelation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011;123:282–291
33. Wang KC, Chang HF. Molecular mechanisms of long noncoding RNAs. Mol Cell 2011;43:904–914
34. Hollander MC, Alamo I, Fornace AJ Jr. A novel DNA damage-inducible transcript, gadd7, inhibits cell growth, but lacks a protein product. Nucleic Acids Res 1996;24:1589–1593
35. Liu X, Li D, Zhang Y, Guo M, Zhan Q. Long non-coding RNA gadd7 interacts with TDP-43 and regulates Cdk6 mRNA decay. EMBO J 2012;31:4415–4427
36. Yan B, Tao ZF, Li XM, Zhang H, Yao J, Jiang Q. Abrupt expression of long noncoding RNAs in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2014;55:941–951
37. Liu JY, Yao J, Li XM, et al. Pathogenic role of IncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 2014;5:e1506
38. Yan B, Yao J, Liu JY, et al. lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res 2015;116:1143–1156
39. Moran I, Akerman I, van de Bunt M, et al. Human beta cell transcriptome analysis uncovers IncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes. Cell Metab 2012;16:435–448
40. Reddy MA, Chen Z, Park JT, et al. Regulation of inflammatory phenotype in macrophages by a diabetes-induced long noncoding RNA. Diabetes 2014;63:4249–4261
41. Giannakakis A, Zhang J, Jenjaroenpun P, et al. Contrasting expression patterns of coding and noncoding parts of the human genome upon oxidative stress. Sci Rep 2015;5:9737
42. Avitabile D, Bailey B, Cottage CT, et al. Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin. Proc Natl Acad Sci U S A 2011;108:6145–6150
43. Kumazawa T, Nishimura K, Katagiri N, Hashimoto S, Hayashi Y, Kimura K. Gradual reduction in rRNA transcription triggers p53 acetylation and apoptosis via MYBBP1A. Sci Rep 2015;5:10854
44. Mroczek S, Kufel J. Apoptotic signals induce specific degradation of ribosomal RNA in yeast. Nucleic Acids Res 2008;36:2874–2888
45. Broedbaek K, Siersma V, Henriksen T, et al. Urinary markers of nucleic acid oxidation and long-term mortality of newly diagnosed type 2 diabetic patients. Diabetes Care 2011;34:2594–2596
46. Kraft C, Deplazes A, Sohrmann M, Peter M. Mature ribosomes are selectively degraded upon starvation by an autophagy pathway requiring the ubp3p/Br6p ubiquitin protease. Nat Cell Biol 2008;10:602–610
47. Pain VM, Garlick PJ. Effect of streptozotocin diabetes and insulin treatment on the rate of protein synthesis in tissues of the rat in vivo. J Biol Chem 1974;249:4510–4514
48. Torres AG, Battie E, Ribas de Pouplana L. Role of tRNA modifications in human diseases. Trends Mol Med 2014;20:306–314
49. Begley U, Dyavaiah M, Patil A, et al. Trm9-catalyzed tRNA modifications link translation to the DNA damage response. Mol Cell 2007;28:860–870
50. Chan CT, Pang YL, Deng W, et al. Reprogramming of tRNA modifications controls the oxidative stress response by codon-biased translation of proteins. Nat Commun 2012;3:937
51. Thompson DM, Parker R. Stressing out over tRNA cleavage. Cell 2009;138:215–219
52. Saikia M, Krokowski D, Guan BJ, et al. Genome-wide identification and quantitative analysis of cleaved tRNA fragments induced by cellular stress. J Biol Chem 2012;287:42708–42725
53. Ivanov P, Emara MM, Villen J, Gygja SP, Anderson P. Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell 2011;43:613–623
54. Sonenberg N, Hinnebusch AG. New modes of translational control in development, behavior, and disease. Mol Cell 2007;28:721–729
55. Kiss T. Small nucleolar RNAs: an abundant group of noncoding RNAs with diverse cellular functions. Cell 2002;109:145–148
56. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006;311:230–232
57. Ender C, Krek A, Friedlander MR, et al. A human snoRNA with microRNA-like functions. Mol Cell 2008;32:519–528
58. Holley CL, Li MW, Scruggs BS, Matkovich SJ, Ory DS, Schaffer JE. Cytosolic accumulation of small nucleolar RNAs (snoRNAs) is dynamically regulated by NADPH oxidase. J Biol Chem 2015;290:11741–11748
59. Cole JL. Activation of PKR: an open and shut case? Trends Biochem Sci 2007;32:57–62
60. Nakamura T, Furuhashi M, Li P, et al. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010;140:338–348
61. Youssef OA, Safran SA, Nakamura T, Nix DA, Hotamisligil GS, Bass BL. Potential role for snoRNAs in PKR activation during metabolic stress. Proc Natl Acad Sci U S A 2015;112:5023–5028
62. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014;13:622–638
63. Rottman N, Price N, Pati P, Goedeke L, Fernandez-Hernando C. microRNAs in lipoprotein metabolism and cardiometabolic disorders. Atherosclerosis 2016;246:352–360